Results 181 to 190 of about 246,840 (252)

Adjuvant Chemotherapy and Immunotherapy in Upper Tract Urothelial Carcinoma: Where Do We Stand? [PDF]

Cancers (Basel)
Carbunaru S, Rich JM, Murray KS.
europepmc   +1 more source

Atomically precise metal cluster enzymes for pathological tissue regeneration

BMEMat, EarlyView.
Schematic illustration of atomically precise metal cluster enzymes (MCEs) for pathological tissue regeneration. Atomically precise MCEs can modulate biological processes, such as attenuation of inflammatory responses, eradication of bacterial pathogens, regulation of angiogenesis, and promotion of cell development.
Ziqiang Xiong, Zhifeng Shi, Mengqing Li, Jien Han, Haoyan Chen, Maofei Ran, Shaojian Zhong, Limin Ma, Chengyun Ning, Youzhun Fan, Zhenghua Tang, Peng Yu   +11 more
wiley   +1 more source

The evaluation of serum magnesium and calcium/magnesium ratio in patients with breast cancer receiving adjuvant chemotherapy. [PDF]

Rep Pract Oncol Radiother
Grupińska J, Kycler W, Dzieniszewski D, Kaja E, Kubicka A, Gryszczyńska B, Brzeziński JJ, Iskra M, Formanowicz D, Idaszewska N, Leporowska E, Budzyń M.   +11 more
europepmc   +1 more source

Mimic, target, and adapt: Cell membrane‐coated nanoplatforms for precision and immune‐guided cancer treatment

BMEMat, EarlyView.
This Perspective explores the emerging landscape of cell membrane‐coated nanoparticles (CM‐NPs) as intelligent, immune‐compatible platforms for cancer therapy. Highlighting design strategies, translational challenges, and competitive positioning, it outlines how integrating biomimetic targeting with advanced analytical and manufacturing tools could ...
A. K. M. M. Alam, Xiaojun Cai, Malik Ihsan Ullah Khan, Robert Musiol, Quazi T. H. Shubhra   +4 more
wiley   +1 more source

Prognostic Value of Ki-67 and Progesterone Receptor for Risk Stratification and Outcomes by Adjuvant Chemotherapy in Early Luminal-Type Breast Cancer. [PDF]

Breast Cancer (Dove Med Press)
Chen HH, Chang SJ, Kan JY, Chen FM, Li CL, Takahashi H, Shih SL, Hou MF, Pan MR, Yang PF, Luo CW.   +10 more
europepmc   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

BMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li, Honglin Huang, Qianyi Zeng, Li Zeng, Ziman Yang, Jinyang Shen, Shun Li, Hong Yang, Yiyao Liu, Chunhui Wu   +9 more
wiley   +1 more source

Quality of life-before and after treatment. A quantitative study of women with breast cancer receiving neoadjuvant or adjuvant chemotherapy

Cederholm C, Nilsson M, Oliva D.
europepmc   +1 more source

Risk of second primary malignancies after adjuvant chemotherapy for colon cancer. [PDF]

Cancer
Buchler T, Ambrozova M, Majek O, Dianova T, Klika P, Dusek L.   +5 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: where do we stand? [PDF]

BMJ Oncol
Yip PL, Lee SF, Chua M.
europepmc   +1 more source